Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | General Counsel and Secretary | March 05, 2026 | March 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date March 05, 2026 · Filed March 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2036-03-05 | Direct | 900,000 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 900,000 · Balance 900,000 F1: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 7, 2026 00:48 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 900,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001193125-26-097181 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Shares · 900,000 shares Expires 2036-03-05 F1 · derivative.exercise_date: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 6,075 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-052020 · ownership.xml · derivative · entry 3 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares | 2,502 | $1.80 | $4,503.60 |
DisclosureSEC source: 0001193125-26-052020 · ownership.xml · nonDerivative · entry 2 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,063 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,075 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares | 6,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-052020 · ownership.xml · nonDerivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| December 19, 2025 Filed Dec 20, 2025 02:55 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares | 65 | $1.68 | $109.20 |
DisclosureSEC source: 0001193125-25-327279 · ownership.xml · nonDerivative · entry 2 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,490 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 1,735 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof. Read SEC document |
| December 19, 2025 Filed Dec 20, 2025 02:55 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantCommon Shares | 1,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-327279 · ownership.xml · nonDerivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,555 F1 · shares: Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000950170-25-038113 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Shares · 750,000 shares Expires 2035-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 6,076 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-018897 · ownership.xml · derivative · entry 3 Samuel George A. III · CIK 0001878732 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,075 Underlying: Common Shares · 6,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares | 2,440 | $0.65 | $1,586.00 |
DisclosureSEC source: 0000950170-25-018897 · ownership.xml · nonDerivative · entry 2 Samuel George A. III · CIK 0001878732 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,820 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares | 6,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-018897 · ownership.xml · nonDerivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| November 26, 2024 Filed Nov 26, 2024 21:55 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 15,000 | $0.60 | $9,000.00 |
DisclosureSEC source: 0000950170-24-131093 · ownership.xml · nonDerivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,184 Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001493152-24-009384 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Shares · 650,000 shares Expires 2034-03-07 F1 · derivative.exercise_date: One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 02:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 6,076 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-005944 · ownership.xml · derivative · entry 3 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,151 Underlying: Common Shares · 6,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 02:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 2,490 | $1.08 | $2,689.20 |
DisclosureSEC source: 0001493152-24-005944 · ownership.xml · nonDerivative · entry 2 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,184 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 02:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 6,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-005944 · ownership.xml · nonDerivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 09, 2023 Filed Mar 11, 2023 00:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001493152-23-007308 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Shares · 650,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 6,076 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-004899 · ownership.xml · derivative · entry 3 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,227 Underlying: Common Shares · 6,076 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 2,478 | $1.35 | $3,345.30 |
DisclosureSEC source: 0001493152-23-004899 · ownership.xml · nonDerivative · entry 2 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,598 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 6,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-004899 · ownership.xml · nonDerivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 01:44 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001493152-22-006698 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Shares · 650,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:45 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 24,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004720 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,303 Underlying: Common Shares · 24,303 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share. F2 · derivative.exercise_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (right to buy) · Derivative | 695,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001493152-21-021880 · ownership.xml · derivative · entry 1 Samuel George A. III · CIK 0001878732 · General Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,000 Underlying: Common Shares · 695,000 shares Expires 2031-09-01 F1 · derivative.exercise_date: This option will vest as to one quarter of the shares subject to the option on September 1, 2022, and the balance will vest in 36 successive substantially equal monthly installments thereafter, subject to the reporting person's continuous employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.